Hormone naïve advanced prostate cancer is subdivided into two disease states: biochemical recurrence and traditional M1 (metastatic) prostate cancer and characterized by no prior hormonal therapy or androgen deprivation therapy (ADT). In biochemical recurrence/prostate-specific antigen (PSA) recurrence, men should be risk-stratified based on their PSA doubling time, the Gleason score and the ti...

OBJECTIVE Circulating tumor cells (CTCs) have known prognostic implications in metastatic castration-resistant prostate cancer, but little is known regarding its utility in biochemical recurrence (BR) of prostate cancer. The primary objectives were to determine whether CTCs are measurable in patients with BR and whether it can reliably predict prostate-specific antigen (PSA) increase and PSA do...

OBJECTIVE To determine if a concurrent diagnosis of diabetes mellitus is associated with worse outcomes in advanced prostate cancer (PC). The effect diabetes may have on the progression of advanced PC is poorly understood. METHODS Data on 148 advanced PC patients (35 with concurrent diabetes) were collected from an institutional database to obtain diabetic status, data on treatment types and ...

Abstract Background Dyslipidemia is directly related to morbidity and mortality in elderly prostate carcinoma patients. The purpose of this study was evaluate the effects androgen deprivation therapy (ADT) on lipid profile among Indian patients with locally advanced metastatic carcinoma. Methods prospective database patients, who received ADT whose data for first two years treatment available, ...

INTRODUCTION The advent of prostate specific antigen (PSA) has resulted in an increased incidence of early detection of prostate cancer recurrence. Patients treated with androgen deprivation therapy (ADT) become hormone-resistant after 18 to 24 months. In patients with biochemical failure, where there is a rise in PSA but no objective evidence of metastases, or in whom there are small volume me...

218 Background: Approximately 10% of patients who undergo a radical prostatectomy (RP) for localized prostate cancer subsequently experience a local recurrence. A small percentage of these patients present with prostate bed nodules (PBN). We present here, a case series of 12 patients treated with low dose rate brachytherapy (BT) for a PBN post RP. METHODS All 12 patients had biopsy confirmed ...

OBJECTIVE To present a management algorithm for men with prostate cancer recurring after external beam radiotherapy (EBRT), based on a review of published reports, to assist clinicians in identifying men who are suitable for salvage therapy and to help them to decide which type of salvage treatment is most likely to confer the desired outcome with the minimum of harm. METHODS Men with radiore...

Objective: To compare finasteride plus flutamide versus flutamide alone in men with biochemically recurrent prostate cancer. Design/Methods: This was a non-randomized phase II study which enrolled 56 men with biochemically recurrent prostate cancer. Men were sequentially assigned to their treatment arm. The first 36 were treated with combination low-dose flutamide plus finasteride while the sub...